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Researchers have linked dementia to common psychiatric symptoms such as agitation 
and aggression, known as behavioral and psychological symptoms of dementia (BPSD). 
To treat residents manifesting BPSD, nursing homes (NHs) use psychoactive 
medications. However, research is limited and inconsistent regarding the impact of 
Depakote treatment on agitation and short-term memory (STM) in NH residents who 
have dementia. The purpose of this nonexperimental quantitative study was to evaluate 
for 1 year the impact of Depakote treatment on agitation and STM in NH residents as 
measured by each resident’s Minimum Data Set (MDS). Moncrieff and Cohen’s drug-
centered theory served as the theoretical foundation for the study. Archival data from the 
consulting pharmacist and NH MDS included 16 NH dementia residents. Data were 
analyzed using a repeated-measures within-subject ANOVA. Results indicated no 
significant impact of Depakote treatment on agitation and STM scores over a 1-year 
period. Results may be used to assess the impact and efficacy of a common yet largely 
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Chapter 1: Introduction to the Study 
Dementia, a progressive and irreversible loss of cognitive functioning caused by 
brain cell damage (Desai, Heaton, & Kelton, 2012), affects approximately 5 to 8 million 
Americans. More than half of those afflicted have common psychotic symptoms along 
with aggression, agitation, and cognitive decline (Mittal, Kurup, Williamson, Muralee, & 
Tampi, 2011). These symptoms collectively are termed behavioral and psychological 
symptoms of dementia (BPSD). BPSD is the most common reason for nursing home 
(NH) admission (Meinhold et al., 2005), and psychoactive medications (e.g., Depakote) 
are the most common treatment for BPSD in the NH setting (Richter, Mann, Meyer, 
Haastert, & Köpke, 2011). However, there is only limited research on the impact of this 
treatment. Studies (Desai et al., 2012; Mittal et al., 2011) showed inconsistent results 
among disparate populations. The current quantitative study addressed the impact of 
Depakote on agitation and short-term memory (STM) in NH residents with dementia over 
a 1-year period. Positive social change implications included (a) contribution to the 
limited extant research on this important subject and (b) assessment of the impact and 
efficacy of a common yet largely unexamined invasive treatment on an underserved, 
vulnerable population. 
Chapter 1 provides a brief overview of research literature related to the impact of 
Depakote on agitation and STM in NH residents with dementia and the research gap on 
this topic. Also, the significance of the research problem to the field of psychology is 





described. Chapter 1 also includes the research questions and null and alternative 
hypotheses, including an explanation of how they related to the study approach and 
research questions. Next, the nature of the study (including design, variables, and 
methodology) is discussed. Definitions are provided for operative variables and terms. 
Finally, assumptions, scope, limitations, and significance of the study are discussed.  
Background 
Dementia is common in the older adult population and is characterized by 
agitation, aggression, disorientation, cognitive decline, verbal and physical outbursts, and 
decline in eating, sleeping, walking, and talking (Dharmarajan & Gunturu, 2009). These 
characteristics of dementia—collectively referred to as BPSD—affect not only the 
individual with dementia but also his or her loved ones and caregivers. The impact of 
dementia on the afflicted individual’s support system often leads the family to turn to 
nursing homes (NHs). According to Dutcher et al. (2014), 30-40% of individuals with 
Alzheimer’s Disease (AD) and other forms of dementia in the United States reside in 
NHs, where psychoactive medications (e.g., Depakote) are the most common treatment 
(Richter et al., 2011). Depakote is an anticonvulsant medication often used to manage 
agitation, which occurs in most NH residents with dementia (Meeks & Jeste, 2008). 
Although there is a vast amount of literature regarding Depakote used for agitation and its 
effects on cognition, the studies indicated inconsistent results. Dutcher et al. (2014) 
reported Depakote had no significant effect on slowing cognitive decline; in contrast, 





the literature regarding the impact of Depakote on agitation and STM in NH dementia 
residents. The current study addressed that gap and helped provide avenues for social 
change by providing new information on the most common treatment (i.e., Depakote) for 
a prevalent and exigent societal problem (i.e., BPSD). 
Problem Statement 
Although the most ostensible feature of dementia is a cognitive decline, 
behavioral disturbances, also referred to as neuropsychiatric symptoms or BPSD, are 
often present and cause difficulty in managing NH residents with dementia (Pinheiro, 
2008). BPSD, which commonly manifests as agitation, has no FDA approved treatment 
(Desai et al., 2012). Although various treatment options exist for BPSD in NH residents 
with dementia, psychoactive medications continue to be the most widely used to manage 
BPSD despite reports of inconsistent benefits and adverse effects (Rayner, O’Brien, & 
Schoenbachler, 2006). Psychoactive medications, such as the anticonvulsant Depakote, 
have been proven to have adverse effects in NH residents with dementia (Dutcher et al., 
2014). Dolder, Nealy, and McKinsey (2012) postulated that anticonvulsants such as 
Depakote are commonly used to manage agitation and aggression because of a lack of 
alternative treatment options that balance efficacy and safety. Lack of scientific 
consensus in the relevant literature indicated a need for additional studies. The results of 
the current study may be used to assess the impact and efficacy of a common yet largely 





Purpose of the Study 
The purpose of this quantitative study, which included a nonexperimental design, 
was to examine the impact of Depakote on agitation and STM in NH residents with 
dementia within a 1-year period. The independent variable was Depakote treatment, and 
the dependent variables were agitation and STM. The focus of this study was to 
determine to what extent Depakote affects levels of agitation and STM. There was also a 
variable of interest, effect over time (trials). Boxplots were used to determine whether the 
length of time the resident was receiving Depakote had any significant effect on agitation 
and STM scores. 
Research Questions and Hypotheses 
Research Question 1 (RQ1): To what extent does Depakote treatment affect levels 
of agitation in NH dementia residents over a 1-year period? 
H01: There is no statistically significant difference in levels of agitation with 
Depakote treatment over a 1-year period as evidenced by no change in agitation from 
preexisting data in Section E of the MDS. 
Ha1: There is a statistically significant difference in levels of agitation with 
Depakote treatment over a 1-year period as evidenced by decreased agitation from 
preexisting data in Section E of the MDS. 
Research Question 2 (RQ2): To what extent does Depakote treatment affect STM 





H02: There is no statistically significant difference in STM with Depakote 
treatment over a 1-year period as evidenced by no change in STM functioning from 
preexisting data in Section C of the MDS. 
Ha2: There is a statistically significant difference in STM with Depakote 
treatment over a 1-year period as evidenced by decreased STM functioning from 
preexisting data in Section C of the MDS.  
Theoretical Framework for the Study 
Moncrieff and Cohen’s (2009) drug-centered theory was the theoretical 
framework for this study. According to drug-centered theory, psychoactive medications 
are extrinsic substances that alter how the body works, and the advantages and 
disadvantages of psychoactive medication use should be carefully evaluated and 
distinguished from the effects of treatment in general. Drug-centered theory can help 
identify (a) how psychoactive medications interact with/induce experiences of distress 
and (b) when the medicated individual should seek psychological help.  
Previous theories of psychoactive medication prescription acted to counter 
neurochemical substrates of disorders or symptoms (Moncrieff, 2008; Moncrieff, Cohen, 
& Mason, 2009). Neglecting to consider potential psychoactive effects of the psychiatric 
medications have made it difficult for researchers to establish disease-specific actions and 
to distinguish whether outcomes occur because of the medication’s actions on an 
underlying pathological process or as a consequence of being in an altered state 





effects, such as sedation, cognitive slowing, behaviors, altered sense of perception, sleep, 
and psychosis. Drug-centered theory indicates that although evidence of the superiority of 
psychoactive medications might imply disease-specific effects, superior effects can also 
be explained within a drug-centered framework, which suggests that the characteristic 
psychomotor and emotional restriction induced by psychoactive medications is more 
effective at suppressing psychotic agitation than other sedatives.  
Moncrieff and Cohen’s (2009) drug-centered theory directly related to this study 
by providing residents or staff members the ability to evaluate and report effects of 
Depakote treatment in their particular situations. The drug-centered theory has also 
prompted the psychiatric research community to produce relevant, unbiased information 
about the range of short- and long-term psychoactive medication effects on cognition, 
behaviors, and bodily systems. The drug-centered theory is discussed in more detail in 
the Chapter 2 literature review.  
Nature of the Study 
This quantitative study addressed to what extent Depakote treatment affects levels 
of agitation and STM in NH residents with dementia. Also, levels of agitation and STM 
for Depakote treatment were measured in four intervals over a 1-year period with and 
without random effects. Residents’ levels of agitation and STM were measured using the 
NH’s preexisting quarterly MDS assessments. I used a repeated measures ANOVA 





intervals in a 1-year period, and effect over time (with and without random effects) 
provided adequate statistical power.  
The dependent variables for this study were agitation and STM, and the 
independent variable was Depakote treatment measured by MDS results and scores. 
Many NH residents with dementia receive psychoactive medications with questionable 
benefits. Looking at these variables provided an understanding of how Depakote 
treatment in dementia patients impacted agitation and STM within the sample. 
Variables were analyzed using a repeated-measures within-subject (with and 
without random effects) ANOVA. The repeated-measures ANOVA was the appropriate 
design for this study because it allowed for testing one group while subjecting them to 
repeated measures. This study had one independent variable (Depakote treatment group), 
two dependent variables (agitation and STM), and significant trials effect (trials/multiple 
measures over time), followed up with boxplots to determine whether the length of time 
the resident was receiving Depakote played any significant role in agitation scores and 
STM scores. A repeated measures design was used because all preexisting data were 
measured on each variable.  
I used archival data from an existing dataset. I did not have direct contact with 
residents, which obviated potential ethical issues from dealing with a vulnerable, 
cognitively impaired population. Data were gathered from a consulting pharmacy’s 
database and NH MDS to measure the impact of Depakote on agitation and STM in NH 





who (a) had been diagnosed with dementia, (b) had exhibited BPSD, and (c) had been 
receiving Depakote over a 1-year period. MDS is a tool mandated for use in NHs for 
clinical assessments of all residents covered under Medicare and Medicaid. The MDS 
provides a comprehensive assessment of each resident’s functional capabilities, health-
related issues, behaviors, psychological symptoms, and cognitive functioning. The MDS 
is described in more detail in Chapter 3. 
Definitions of Key Terms 
Agitation: An increased verbal and/or motor activity as well as restlessness, 
anxiety, tension, and fear with or without provocation (Zagaria, 2006).  
Alzheimer’s disease (AD): The most common type of dementia, characterized by 
cognitive impairment, difficulty communicating, poor judgment, disorientation, 
confusion, behavior changes, and difficulty speaking, swallowing and walking 
(Alzheimer’s Association, 2017). 
Behavioral and psychological symptoms of dementia (BPSD): A heterogeneous 
range of psychological reactions, psychiatric symptoms, and behaviors, which may be 
disruptive and unsafe and may impair patient care (Mittal et al., 2011). 
Dementia: A general term for memory loss and other mental abilities caused by 






Depakote: An anticonvulsant medication originally developed to treat epilepsy 
and bipolar disorder and to prevent migraine headaches; it can be given intravenously or 
orally and has long- and short-acting forms (FDA, 2011). 
Psychoactive medications: Drugs or chemical substances that act primarily on the 
central nervous system and alter brain function, resulting in temporary changes in 
behavior, mood, perception, and consciousness (Brandt & Pyhtila, 2013). 
Short-term memory (STM): The type of memory used to retain information for a 
short time; it has a working memory component that is used to manipulate information in 
consciousness (Engle, Laughlin, Tuholski, & Conway, 1999).  
Assumptions 
 I assumed that all residents were NH residents of one of the two local NHs from 
which data were obtained. This assumption was accounted for by obtaining preexisting 
data directly from the two NHs. I also assumed that all residents had a diagnosis of 
dementia. The preexisting data from the pharmacy consultant and the two NHs verified 
residents’ diagnosis of dementia. Next, I assumed that the residents were receiving 
Depakote for BPSD, which was also accounted for by viewing the preexisting data from 
the pharmacy consultant. This dataset included the reason why the residents were 
receiving Depakote. I assumed that assessment tools used in this study were appropriate 
for the identified sample of NH residents with dementia on Depakote treatment for 
agitation. I assumed all data gathered were preexisting data from NH MDS and pharmacy 





members completing the MDS had the clinical knowledge/competency to do so. I 
assumed that anonymity and confidentiality were preserved by using preexisting data and 
that use of these data obviated potential ethical concerns.  
Scope and Delimitations 
 I examined the impact of Depakote on agitation and STM in NH dementia 
residents over a 1-year period. This area was chosen for this study because prior research 
indicated adverse effects of psychoactive medications but revealed a gap on the impact of 
Depakote on agitation and STM in NH dementia residents over a 1-year period. The 
sample was chosen to represent NH residents receiving Depakote for BPSD. This study 
did not include unmeasured variables, such as gender, race, and age, because of the 
smaller sample size. Residents receiving Depakote for seizure disorder were excluded. 
Prior research indicated adverse effects of Depakote, but this study looked specifically at 
the impact of Depakote on agitation and STM in NH dementia residents within a 1-year 
period. The primary issues of validity were anticipating that NH social workers who 
completed preexisting MDSs provided correct information regarding each resident’s 
behavior and cognition. 
Limitations 
 Limitations of this study pertained to potential problems with the study design. 
For example, the NHs where the data were gathered represented only the United States 
and may not represent the entire NH population. Data were drawn from a specific 





had been on Depakote treatment for one year and (b) Depakote having been prescribed 
specifically for BPSD. This study did not include every race, age bracket, geographic 
background, or socioeconomic status represented in the NHs. Threats to external validity 
related to repeated measures because it was difficult to control for the effects of prior 
outcomes using the same subject. 
Another factor that contributed to limitations in this study was the lack of primary 
data (i.e., depending exclusively on accurate MDS assessments). Data in MDS and 
pharmacy records may not have been meticulously and accurately collected. However, 
because of the vulnerable nature of the target population, it was best to use preexisting 
data to avoid ethical complications when gathering the data. Clear directions were given 
to the NH and pharmacy contacts regarding the specific sections needed from MDS 
records and pharmacy records (i.e., only residents who had been on Depakote for BPSD 
for at least one year, with seizures excluded). Nevertheless, there were factors that could 
have jeopardized internal validity (e.g., if the scorer of the MDS changed, there may have 
been outcome changes). Precautions were taken to maintain the confidentiality of the data 
provided, and NH administrators and pharmacy representatives were informed that the 
study would be confidential. 
Significance of the Study 
Over the last century, there has been a dramatic increase in psychoactive 
medication use due to the increase in the geriatric population, and patient 





considerably (Hilmer, McLachlan, & Le Couteur, 2007). There is limited evidence 
regarding the complexities of geriatric pharmacology, and it is underappreciated in 
clinical trials.  
According to Spira and Edelstein (2007), agitation is exhibited by 55% to 90% of 
individuals with dementia with various approaches and treatments attempted. 
Psychoactive medications are prescribed to up to a third of older adults and are the most 
widely used medications in NHs to treat agitation, Depakote being one of them 
(Huybrechts et al., 2012). Understanding potential connections between agitation and 
STM with Depakote treatment may contribute to positive social change by raising 
awareness regarding concerns of the NH dementia population that may have been 
overlooked. It is important to understand the theoretical concepts behind psychoactive 
medication use, agitation, and memory in those with dementia. It is essential to treat these 
symptoms in this population, but research indicated that there had not been any 
therapeutic solutions and Depakote continues to be used for these purposes. This study 
addressed that gap by examining the impact of Depakote on agitation and STM in NH 
dementia residents over a 1-year period. Findings from this study may provide insight on 
the impact of Depakote used to treat agitation and its adverse effects about agitation and 
STM. Findings may provide updated information related to NH use of Depakote for 






Chapter 1 provided a brief overview of existing literature on the study topic, 
including a gap in the literature regarding the impact of Depakote treatment on agitation 
and STM. I gave a brief description of drug-centered theory as the theoretical framework 
for this study. The NH is a unique environment that requires workers to be trained to deal 
with dementia and BPSD. BPSD is difficult to manage in NH dementia residents, and 
therefore psychoactive medications are often used (Meeks & Jeste, 2008). Studies 
showed Depakote treatment as inconsistent, with positive and negative effects. Despite 
conflicting findings and safety warnings concerning the use of psychoactive medications 
in NH residents, Depakote treatment has remained common because of longer resident 
lifespans and an increased number of people with dementia (Huybrechts et al., 2011). 
This study contributed to the body of literature by addressing the impact of Depakote 
treatment on agitation and STM in NH dementia residents over a 1-year period. 
Implications for social change include assessing the impact and efficacy of a common yet 
largely unexamined invasive treatment on an underserved, vulnerable population. 
Chapter 2 provides a more comprehensive overview of drug-centered theory, which 
provided the theoretical framework for studying the impact of Depakote on agitation and 
STM in NH dementia residents within a 1-year period. Chapter 2 also addresses 







Chapter 2: Literature Review 
A review of the literature produced a limited number of studies on the impact of 
Depakote on agitation and STM in NH dementia residents. The purpose of this 
nonexperimental quantitative study was to go beyond the boundaries of the current 
literature to examine the impact of Depakote treatment on agitation and STM in NH 
dementia residents over a 1-year period. The focus was on the extent to which Depakote 
affects levels of agitation and STM. The Depakote treatment group was the independent 
variable; agitation and STM were the dependent variables. I employed a within-subject 
design (trials/effects over time), including repeated measures for all variables. 
Additionally, I employed boxplots to determine whether the length of time resident was 
receiving Depakote had any significant effect on agitation scores and STM scores. 
Depakote is an anticonvulsant medication used to manage agitation in 
approximately 80% of NH residents with dementia (Meeks & Jeste, 2008). Medicare 
reports show dementia affects approximately 5 to 8 million Americans, of which more 
than half have BPSD (Mittal et al., 2011). According to Dutcher et al. (2014), 30-40% of 
individuals with AD and other forms of dementia in the United States reside in NHs. 
BPSD is a major reason for increased agitation and cognitive decline, for which there is 
no FDA approved treatment (Desai et al., 2012).  
The following literature review includes the most current research relating to NH 
residents with a diagnosis of dementia who are prescribed Depakote for BPSD. The 





dementia resident behaviors, psychological symptoms, and cognition. This chapter begins 
with a description of the literature search strategy. The next section contains a review of 
literature on Moncrieff and Cohen’s (2009) drug-centered theory and is followed by a 
review of studies on psychoactive medication use in NH dementia residents, Depakote 
use in NH dementia residents, adverse effects of Depakote use in NH dementia residents, 
benefits of Depakote use in NH dementia residents, BPSD and Depakote use in NH 
dementia residents, Depakote and agitation in NH dementia residents, Depakote and 
cognitive functioning in NH dementia residents, and Depakote and STM in NH dementia 
residents. Next is a review of studies that addressed Depakote use to manage agitation in 
NH dementia residents, a review that exposes inconsistencies in findings and effects of 
Depakote use to manage agitation in NH dementia residents. Some of the studies cited in 
this literature review involved the use of MDS to obtain measures of behavior and/or 
cognitive functioning (i.e., the same database that was used in the current study). Finally, 
the study variables are discussed (i.e., Depakote use, agitation, and STM), and an 
explanation for the impact of Depakote on agitation and STM in NH dementia residents 
is provided. The chapter concludes with a rationale for the choice of research method, a 
summary of the literature review, and suggestions for additional research. 
Literature Search Strategy 
 The databases used to discover the literature were accessed through the Walden 
University Library; the databases included PsychINFO, SAGE Premier, Academic 





Central. I also used the Google Scholar search engine. The following keywords, terms, 
and phrases were used: dementia, AD, agitation, BPSD, STM, cognition, Depakote, NH 
residents, psychoactive medications, Depakote and agitation and dementia, Depakote 
and BPSD, Depakote and agitation and NH residents, Depakote and NH, effects and 
Depakote and agitation, Depakote and cognition, Depakote and STM and dementia, 
Depakote and AD, and psychoactive medications and NH. Most of the literature was 
found using SAGE Premier and Google Scholar, and the search using the phrase 
Depakote and BPSD yielded the most literature. Initial searches were performed in 
October 2015, and additional searches were conducted for new references in May 2016, 
July 2016, and January 2017. 
Theoretical Foundation: Drug-Centered Theory 
The theoretical framework for this study was Moncrieff and Cohen’s (2009) drug-
centered theory, which states that because psychoactive medications are extrinsic 
substances altering how the body works, advantages and disadvantages of psychoactive 
medication use should be weighed and distinguished from the effects of treatment in 
general. Drug-centered theory can inform perspectives about how psychological 
alterations produced by psychoactive medications interact with experiences of distress 
and the need to seek psychological help. Many disorders can mimic psychoactive effects, 






Moncrieff and Cohen (2009) theorized that although evidence of the superiority 
of psychoactive medications might imply disease-specific effects, superior effects can 
also be explained within a drug-centered framework (e.g., the psychomotor and 
emotional restriction characteristic of psychoactive medications suppresses psychotic 
agitation more effectively than other sedatives). The drug-centered theory provides a 
useful lens through which NH resident clinicians or staff members can evaluate and 
report the effects of Depakote treatment in NH dementia residents. The drug-centered 
framework further prompts members of the psychiatric research community to produce 
relevant, unbiased information about the short- and long-term effects of psychoactive 
medications on cognition, behaviors, and bodily systems. 
Literature Review Related to Key Variables 
Overview of Psychoactive Medication Administration in Treating BPSD in NH 
Dementia Residents 
 Throughout much of the literature reviewed, dementia-associated psychotic 
symptoms have been labeled BPSD, which represents the most difficult dementia 
sequelae for NHs to manage. BPSD is often discussed in the literature as a heterogeneous 
range of psychological reactions, psychiatric symptoms, and behaviors, which can be 
disruptive and unsafe and can impair the care of the resident in a given environment; 
moreover, the likelihood and intensity of BPSD increase as dementia progresses (Mittal 





Meeks and Jeste (2008) conducted a meta-analysis of 15 randomized controlled 
trials involving psychoactive medications including risperidone, olanzapine, aripiprazole, 
and quetiapine used to treat agitation or psychosis in NH dementia residents. Most 
residents were female NH residents with AD. Meeks and Jeste found that psychosis 
improved with risperidone, and neuropsychiatric disturbances improved with risperidone 
and aripiprazole. Meeks and Jeste also noted that effects were more noticeable in 
residents without psychosis, NH residents, and residents with severe cognitive 
impairment. In contrast, subsequent placebo-controlled trials of risperidone, quetiapine, 
and aripiprazole in AD residents revealed that atypical and typical antipsychotics are 
effective in reducing aggression and psychosis (Meeks & Jeste, 2008). Although these 
findings suggested that psychoactive medications are effective in treating BPSD, the 
results were questioned by the National Institute of Mental Health (NIMH) Clinical 
Antipsychotic Trial of Intervention Effectiveness Study for Alzheimer’s Disease 
(Lieberman, 2006). This NIH-sponsored study indicated that risperidone and olanzapine 
but not quetiapine were effective in that fewer residents taking them versus placebo 
dropped out due to lack of efficacy. The year-long study indicated that antipsychotics 
were not effective overall because of the primary outcome, all-cause discontinuation rate, 
was similar for all three drugs and placebo. The result suggested a muddled, inconclusive 
picture regarding the efficacy of psychoactive medication administration for treating 





examination of a prevalent treatment program for a pressing societal problem, a need 
addressed by this study. 
Risks of Psychoactive Medication Use in NH Dementia Residents 
There are no drugs that have been FDA approved to treat BPSD in dementia 
residents, but psychoactive medications are often used to alleviate these symptoms 
(Meeks & Jeste, 2008). One of the most concerning issues regarding NH administration 
of psychoactive medications is they present a safety hazard and are linked to a variety of 
negative outcomes (Molinari et al., 2013). In the NH setting, negative outcomes include 
cerebrovascular effects, heart failure, and sudden death (Schneider, Dagerman, & Insel, 
2006). According to Meeks and Jeste (2008), the likelihood that NH residents are on a 
variety of medications for various health issues further complicates the administration of 
psychoactive medications, thereby increasing the chances for adverse drug reactions and 
potentially increasing psychosis and agitation.  
BPSD Versus Other MH Symptoms 
There are many side effects from psychoactive medication use in NH dementia 
residents. For example, NH residents with dementia face greater risk of hospitalization, 
falls, cognitive impairment, and mortality (Ballard et al., 2009, 2011; Belleville, 2010; 
Cooper, Freeman, Cook, & Burfield, 2007; Dragonich, Zancy, Klafta, & Karrison, 2001; 
Frey, Ortega, Wiseman, Farley, & Wright, 2011). BPSD represents just one of the 
prevailing mental health (MH) concerns among the NH population. According to 





categorized as having BPSD rather than being carefully evaluated for other MH issues. 
Using the benchmarks of decreased numbers of falls and hospitalizations, Molinari et al. 
addressed the question of whether providing an MH assessment to all NH residents upon 
admission would decrease the use of psychoactive medications. The study was conducted 
at four for-profit NHs and included 23 residents who were cognitively able to provide 
valid responses. These results were compared to a group of 23 NH residents who did not 
receive MH assessments. Using a chi-square analysis, Molinari et al. found at a 1-month 
follow-up comparing the assessment and nonassessment groups on various measures of 
psychopharmacological and nonpsychopharmacological interventions that the residents 
who received brief MH assessments were less likely to start on psychoactive medications 
despite the fact that a high number of residents were admitted to the facility with orders 
for psychoactive medications. Molinari et al. also revealed that despite favorable 
comparisons with the nonassessment comparison group, psychoactive medication use 
was still high in the assessment group, and the intervention was not helpful in getting 
residents off psychoactive medications. 
In other words, Molinari et al. (2013) found that consideration of alternative ways 
of addressing residents’ MH needs decreased the likelihood of starting residents on 
psychoactive medications. Also, Molinari et al. found that residents who received the MH 
assessment were also more likely to receive subsequent MH consultation. This finding is 
significant in that it shows a positive correlation between consideration of alternative MH 





used to minimize previously demonstrated negative impacts of psychoactive medication 
administration on NH residents with dementia. However, the study would have benefitted 
from larger sample size and more diverse demographics, which would have increased 
study power and validity. The sample was disproportionately non-Hispanic White and 
comprised short-stay residents.  
Psychoactive Medications on Mental, Behavioral, and Physical Health 
Richter et al. (2011) found that psychoactive medications induce a distinctive 
alteration in mental and physical states when used to treat BPSD in NH residents with 
dementia. Moncrieff, Cohen, and Porter (2013) addressed how the effects of psychoactive 
medications might modify various psychiatric symptoms. For example, psychoactive 
effects can directly modify mental and behavioral symptoms and affect the results of 
placebo-controlled trials. Although the term psychoactive is related to mental alterations, 
mental conditions are connected to physical conditions, causing a global effect. 
Moncrieff et al. concluded that despite much of the research in neuropharmacology, more 
extensive research is needed to clarify the long-term mental, behavioral, and physical 
effects of psychoactive medications. Such research would assist in diagnosis and 
treatment and enable further discussion of the purpose and ethics of the frequent use of 
psychoactive medications to manage behaviors in older adults.  
Prevalence of Psychoactive Medication Use in NH Dementia Residents 
Much of the literature addressed the challenges for NHs in managing BPSD as 





medications. Previous research indicated psychoactive medications are the most widely 
used medications among NH residents and that 50% to 80% of residents are on at least 
one psychoactive medication (Meinhold et al., 2005; Richter et al., 2011). Richter et al. 
(2011) looked at the comparison of four different variables (i.e., psychoactive 
medication, different classes of psychoactive medication, psychoactive medication 
administered for bedtime only, and associations between prescription of psychoactive 
medications and institutional and resident characteristics). Richter et al. conducted a 
cross-sectional comparison of data from three large studies of 5,336 NH residents from 
136 long-term care facilities. Richter et al. found that in all three comparison studies, 
74.6%, 51.8%, and 52.4% of all residents were on at least one psychoactive medication. 
Another comparison indicated that 66% and 47% of residents were prescribed for 
bedtime use only. None of the three studies indicated a statistically significant association 
between psychoactive medication prescription and NH characteristics; however, 
consistent positive associations were found for a higher level of care dependency and 
permanent restlessness, and consistent negative associations were found for older age and 
male gender. In other words, residents requiring more care and presence of permanent 
restlessness had a higher rate of psychoactive medications prescribed. These findings 
provide evidence that psychoactive medications are highly prevalent in managing BPSD 
in NH residents. The researchers were not able, however, to show a correlation between 
NH characteristics and psychoactive medication prescription rates. In contrast, despite the 





prescriptions on a nurse staffing level. Specifically, it was found that psychoactive 
medications are the first course of treatment for BPSD and that there is a need for 
effective programs to reduce prescription of psychoactive medications in NH residents. 
Impact of Depakote on Agitation in NH Dementia Residents 
 Agitation affects up to 70% of older adults with dementia, and Depakote 
derivatives have been used for more than ten years to control agitation in dementia 
residents in NHs (Narayana, Clifton, Luxenberg, & Curran, 2014). The Narayana et al. 
2014 review examined whether the evidence supports the use of Depakote in the 
treatment of agitation in dementia residents. The review concluded that Depakote does 
not improve agitation in dementia but increases the frequency of side effects. Within the 
body of literature that has focused on using Depakote for agitation in NH dementia 
residents, there is limited research discussing the impact of Depakote on agitation and 
STM in NH dementia residents. 
Advantages of Depakote Use in NH Dementia Residents 
BPSD is known to occur in up to 90% of individuals with dementia at some point 
in their disease progression (Meinhold et al., 2005). There are many different 
manifestations of dementia, including cognitive decline, alterations in 
mood/thought/behavior, and inability to conduct activities of daily living (ADLs). As in 
the Richter et al. study, Meinhold et al. (a) described BPSD as depression, hallucinations, 
delusions, agitation, aggression, combativeness, disinhibition, and hyperactivity and (b) 





patients with dementia. The impact or benefits of psychoactive medications are not 
exclusive to one specific medication; thus, the anticonvulsant agent Depakote may have 
some advantages when used for agitation and aggression in dementia residents due to its 
lower rates of drug interactions and adverse effects in the dementia population. The 
authors addressed the impact of Depakote on behavioral, mood, and cognitive measures 
in NH dementia residents who had a history of behavior problems associated with 
dementia. The researchers utilized pharmacy databases and MDS assessments to obtain 
data for residents that were receiving Depakote for behavior problems related to 
dementia. Some exclusions were applied, such as residents that were receiving Depakote 
for seizures (i.e., the indication for which Depakote is FDA-approved). A total of 450 
residents were identified with behavior problems related to dementia and receiving 
Depakote, and MDS assessments indicated that Depakote reduced the frequency of 
negative behaviors; expressions of verbal distress; indicators of sad, apathetic and 
anxious appearance; and sleep cycle problems (Meinhold et al., 2005). In sum, the 
authors found the use of Depakote for agitation and aggression in dementia residents was 
effective, safe, and tolerable. They concluded Depakote might have multiple beneficial 
effects in NH dementia residents with a history of dementia with behavioral problems. 
Results further suggested that if Depakote were used as a secondary agent and started 





Disadvantages of Depakote Use in NH Dementia Residents 
The aforementioned results are inconsistent with the results from Narayana et al. 
(2014), who concluded that Depakote is not beneficial for BPSD management in that 
Depakote does not improve BPSD symptoms and increases the frequency of side effects. 
Also, Tariot et al. (2005) compared Depakote and placebo treatments in residents with 
AD. The authors performed three randomized, double-blind, placebo-controlled clinical 
trials in 153 NH residents with AD complicated by agitation, and out of those 153 
residents, 78 were assigned placebo and 75 Depakote. The clinical trial was six weeks in 
length, and Depakote dosages were increased every 3 days until the target dose was 
reached. The authors reported that Depakote did not show benefit over placebo in 
alleviating AD-associated agitation in NH residents. Primary and secondary measures of 
behavior, using the Last Observation Carried Forward (LOCF) and Completer 
approaches, showed consistent results. The authors further reported none of the earlier 
placebo-controlled studies had proved Depakote was effective for agitation in NH 
dementia residents. The Tariot et al. (2005) study was the largest to prospectively address 
agitation as the primary outcome. Previous and subsequent literature regarding the use of 
Depakote for managing agitation in NH dementia residents have reported similar 
findings. Herrman et al. (2007) reached findings along the same lines, reporting Depakote 
is ineffective for managing agitation in NH residents with AD and may be poorly 
tolerated in this population. The authors of the 2007 study discussed similar previous 





Depakote on primary outcome measures, though it showed efficacy for some secondary 
measures. The major limitations of this study were the small sample size and crossover 
design, but despite these limitations, significant worsening of symptoms during Depakote 
treatment was found.  
Impact of Depakote Doses and Levels in NH Dementia Residents  
Herrman et al. (2007) found that lower Depakote doses and slower titration 
schedules could improve tolerability (i.e., longer Depakote treatment phases could prove 
beneficial in managing agitation in NH residents with AD). Similarly, Tariot et al. (2005) 
used Depakote doses and levels similar to those in previous trials (doses are typically 
lower in AD residents versus in those with seizure disorders or mania in younger 
populations). The authors found it highly unlikely that higher doses would have been 
tolerated well enough to justify their use, and they could not conclude that a longer 
treatment period would have been more effective.  
Tolerability and Effectiveness of Depakote in NH Dementia Residents 
Mizukami et al. (2010) addressed the negative impacts of BPSD and how they are 
often managed using psychoactive medications, despite the mortality rate. The authors 
emphasized the urgent need for safer BPSD treatment in dementia patients. The aim of 
their study, similar to Tariot et al. (2005) and Herrman et al. (2007), who reported that 
Depakote was ineffective for managing agitation in NH dementia residents, was to 
examine the efficacy and tolerability of Depakote in patients with BPSD. The study 





(excluding those with reversible causes of dementia or with a diagnosis other than 
dementia [e.g., delusional disorder]). The authors reported that unsteady gait, sleepiness, 
nausea, dizziness, and headache were experienced by 13 of the 110 residents, though 
serum tests showed no abnormal findings. They also found that out of the 110 patients, 
ten were very much improved, 42 much improved, 34 minimally improved, 21 had no 
change, and three worsened (i.e., the very much or much improvement was observed in 
52 out of the 110 patients). They observed some adverse effects such as 
hallucinations/delusions (6/54), irritability/excitement (70/85), aggression/agitation 
(29/43), insomnia/delirium (35/58), inappropriate/purposeless behaviors (11/40), and 
other symptoms not specified (25/46). In contrast to Tariot et al. and Herrman et al., this 
study revealed Depakote was effective in 47.3% of the patients with BPSD without 
experiencing serious adverse effects. The researchers also found Depakote was effective 
in managing irritability, aggression, and agitation while there was no effect on 
hallucinations/delusions and inappropriate behaviors. The authors cited results from 
previous studies that reported the effectiveness of Depakote against agitation and 
aggression in dementia patients. In contrast, results from randomized controlled trials 
have been inconsistent, indicating a need for further research into the impact of Depakote 
on agitation and aggression. Porsteinsson (2006) also addressed the use of Depakote as an 
intervention for BPSD, reporting results from four placebo-controlled trials and 
concluding that none of the studies was sufficient to define clinical practice due to 





had suggested possible short-term efficacy, tolerability, and safety of Depakote for 
agitation and some other neuropsychiatric symptoms associated with dementia patients; 
in the fourth study, there were no demonstrated benefits of Depakote over placebo. The 
author concluded further research is needed to determine optimal use of Depakote for the 
treatment of BPSD and to see if there are any long-term benefits in using Depakote to 
manage BPSD. 
Dolder et al. (2012) reported that the use of anticonvulsants (of which Depakote is 
the most commonly prescribed) had yielded inconsistent results in residents with 
dementia. The authors reported that Depakote had been believed to produce symptomatic 
improvements in dementia due to its actions on GABA and N-methyl-D-aspartate 
(NMDA) receptors. They also reported that in vitro and in vivo studies have 
demonstrated Depakote may have neuroprotective effects on AD due to numerous 
potential mechanisms such as prevention of beta-amyloid aggregation, decreased beta-
amyloid and neuritic plaque production, and induction of neurogenesis. That is, Depakote 
can have positive effects on certain brain functions and chemical reactions in AD 
residents. In contrast, the researchers mentioned that Depakote is not usually 
recommended in evidenced-based treatment guidelines and position statements for 
dementia residents. The authors further discussed conflicting findings over the years 
regarding the use of Depakote in dementia residents for agitation, reporting that older 
reviews were based primarily on open-label and retrospective studies and usually ended 





they reported more recent reviews that indicated controlled trials did not primarily end 
with positive conclusions. As in the Tariot et al. study, residents were institutionalized 
and had a diagnosis of dementia, and all residents are receiving Depakote for a seizure 
disorder, other medical related conditions, and MH diagnoses, were excluded from the 
study. Also, residents that were admitted to NHs with other medical causes (e.g., 
delirium, medication withdrawal, intoxication) for their behavior disturbances were 
excluded. The authors gathered the resident’s demographic, diagnostic, medication, and 
drug-level data from resident charts. The objective of their study was to describe the 
dosages of Depakote among residents admitted to a geriatric ward for dementia-related 
behaviors. The researchers took several subjects into consideration, such as Depakote 
dosages before admission (if applicable) and at discharge, Depakote serum level about 
discharge dose, the weight of the resident, and if the resident was on any antipsychotics 
or benzodiazepines. Twenty studies were included in the Dolder et al. review: 18 of the 
studies examined the effects of Depakote on residents with psychosis or behaviors in 
dementia; another study examined the effects of Depakote to prevent behaviors, and 
another trial investigated the tolerability of Depakote. The average age of residents was 
80, with a diagnosis of AD, and agitation and aggression were the most common 
indications for Depakote use. The authors concluded Depakote might be beneficial in 
some residents with dementia-associated agitation based primarily on lower doses of 
Depakote being associated with symptomatic improvement. In contrast, they reported the 





leaving important questions unanswered. In sum, the researchers reported Depakote does 
not seem to be beneficial in preventing behavioral symptoms and, also, can produce 
problematic side effects in some residents with dementia.  
Gareri et al. (2009) examined Depakote-induced delirium in an AD patient with 
moderate cognitive impairment associated with behavioral disorders, including 
aggression, agitation, and severe insomnia. They reported that, after an initial benefit, the 
patient suddenly developed hyperactive delirium, including worsening of insomnia and 
agitation, severe confusion, delusions, and visual hallucinations alternated to sedation. 
The researchers reported that Depakote was immediately stopped and symptoms 
continued for approximately a week, while another medication was introduced and was 
successful after three more days. This 2009 case study addressed (a) the possible negative 
effects of prescribing Depakote to AD patients to manage agitation and aggression and 
(b) the importance of minimizing the use of and titrating psychoactive medications in 
dementia patients. 
Depakote on Delaying or Preventing the Start of Symptoms and Slowing Cognitive 
Decline 
Tariot et al. (2011) attempted to determine whether Depakote treatment could 
delay or prevent the start of symptoms of agitation or psychosis. The study consisted of 
313 individuals with moderate AD who had not yet experienced agitation or psychosis. 
The researchers utilized a multicenter, randomized, double-blind, placebo-controlled trial 





2-month period of single-blind placebo treatment. The authors reported a total of 122 
residents (59 receiving Depakote and 63 receiving placebo) completed 24 months of 
treatment; 42 (27 receiving Depakote and 15 receiving placebo) reached 24 months 
having discontinued the medication; 150 reached month 26. They found that there was no 
difference between groups in the manifestation of agitation or psychosis and that there 
was no difference in groups in change on any secondary outcome. Results revealed the 
Depakote group had higher rates of somnolence, gait disturbance, tremor, diarrhea, and 
weakness; and 88% of the residents that underwent magnetic resonance imaging (MRI) 
showed greater loss in hippocampal and whole-brain volume, accompanied by greater 
ventricular expansion (Tariot et al., 2011). In conclusion, the authors found Depakote that 
treatment did not delay the start of agitation or psychosis or slow cognitive or functional 
decline in patients with moderate AD, and the medication was associated with significant 
toxic effects. 
Impact of Depakote on STM in NH Dementia Residents 
 When searching the databases listed at the beginning of this chapter, there was 
little to be found on the impact of Depakote on STM, identifying a significant gap in the 
literature. STM is described as the system that temporarily stores and manages 
information that is necessary to complete complex cognitive tasks (Ai-Guo et al., 2015). 
Richter et al., (2015) discussed the effects of person-centered care on psychoactive drug 
use in NHs. The authors discussed the high rates of psychoactive medication use within 





psychoactive medications, many for inappropriate reasons. One of the adverse effects 
they mentioned is diminished cognitive function. Though they mentioned worsening of 
cognitive functioning, their research did not specifically touch on the impact of Depakote 
on STM.  
Impact of Psychoactive Medication on Cognitive Function in NH AD Residents 
Dharmarajan and Gunturu (2009) discussed the high rates of AD in NH residents 
and the possible causes. They described AD as a common, acquired disorder that is 
manifested as slow, progressive memory loss with at least one cognitive dysfunction 
(aphasia, apraxia, agnosia, or executive dysfunction), resulting in impaired occupational 
and social performance. The researchers mentioned the deterioration in cognition from 
earlier levels must occur in the absence of delirium or other causes of dementia (e.g., 
Parkinson’s disease or vascular dementia). The researchers discussed (a) the use of 
psychoactive medications, including Depakote, to manage agitation and difficult 
behaviors in NH dementia residents and (b) the impact of the medication on cognitive 
function. Similar to the Richter study, the authors of the 2009 study touched lightly on 
adverse effects and cognitive functioning but not specifically on STM.  
Case Study on the Negative Impact of Depakote  
Manckoundia et al. (2008) did a case study of a 68-year-old woman who 
developed dementia symptoms after starting Depakote for seizures. Before starting 
Depakote, the woman did not have any neurological complications, but after several 





withdrawal from social activities. The authors reported that her psychological assessment 
revealed memory difficulties, predominantly STM with impairment of recall memory, 
disorientation to time, and difficulty finding words and writing. Her mini-mental 
(MMSE) score was 15, and discrete lesions were evident on an MRI. The researchers 
believed Depakote was the possible cause of the woman’s psychomotor slowing. After 
Depakote was discontinued, the woman experienced rapid clinical and objective 
improvement, and three weeks after stopping Depakote, her psychomotor slowing had 
resolved; her speech was normal; her MMSE score was 25, and she started engaging in 
social activities again. This case study indicated that Depakote had a negative impact on 
short-term memory and when discontinued, STM returned to baseline. 
Impact of Mood Stabilizers on Cognitive Functioning 
Dutcher et al. (2014) researched exposure to medications (such as Depakote) 
commonly used in NH dementia residents. The authors reported that slower cognitive 
decline was associated with antidepressants and antipsychotics, but poorer outcomes 
were observed with mood stabilizers, such as Depakote. The study was a 2-year 
longitudinal investigation of 18,950 NH residents who were newly diagnosed with 
dementia and resided in the NH for at least part of the two-year study period. The authors 
obtained their data from the Chronic Conditions Data Warehouse (CCW) and nursing 
home MDS records. Their study included residents’ exposure to four classes of 
medications: antidementia medications (ADMs), antipsychotics, antidepressants, and 





Cognitive Performance Scale (CPS). Study results indicated ADM was not associated 
with a change in ADLs over time but was associated with a slower CPS decline; 
antidepressant use was associated with slower declines in ADLs and CPS. They reported 
that sex modified the effect of both antipsychotic and mood stabilizer use on ADLs; 
female users declined more quickly than males. They also reported that antipsychotic use 
was associated with slower CPS decline, whereas mood stabilizer use had no effect (i.e., 
Depakote did not have any effect on slower CPS decline). The authors reported that 
despite the statistically significantly slower declines in cognition with ADMs, 
antidepressants, and antipsychotics and the slower ADL decline found with 
antidepressants, it is unlikely that these benefits are of clinical significance. 
Possible Benefits in Cognitive Functioning with Depakote Use 
A study by Ai-Guo et al. (2015) using mice looked at how astrocytes and 
microglia activated by amyloid-β (Aβ) contribute to the inflammatory process that 
develops around an injury in the brain. The authors reported that Depakote had been 
shown to have an anti-inflammatory function, and their study looked to explore the 
therapeutic effect of Depakote on the neuropathology and memory deficits in transgenic 
mice. They reported mice treated with Depakote showed markedly improved memory 
deficits and decreased Aβ deposition compared with the non-Depakote treated mice. 
Also, the extensive astrogliosis and microgliosis, as well as the increased expression in 
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the hippocampus and 





neuronal degeneration. Simultaneously, Depakote alleviated the levels of p65 NF-kB 
phosphorylation and enhanced the levels of acetyl-H3, Bc1-2, and phosphoglycogen 
synthase kinase (GSK)-3β that occurred in the hippocampus of the transgenic mice. 
These results indicate that Depakote could significantly improve spatial memory 
impairment and Aβ deposition, at least about inflammation. The researchers described 
spatial memory as being the part of the memory responsible for recording information 
regarding the environment and spatial orientation, and about STM, the spatial memory 
includes tasks such as learning, reasoning, and comprehension. Similarly, Yao et al. 
(2014) described AD as a very common progressive neurodegenerative disorder that 
affects learning and memory abilities in the brain. The researchers discussed key findings 
from recent studies of epigenetic mechanisms of memory that suggests chromatin 
remodeling disorders via histone hypoacetylation of the lysine residue contribute to the 
cognitive impairment in AD. These findings indicate that the inhibition of histone 
acetylation induced by histone deacetylases (HDACs) inhibitors contributes to the 
recovery of learning memory. This, in turn, indicates it is possible for STM to ameliorate 
during Depakote use. As in the Ai-Guo et al. study, Yao et al. looked at various 
mechanisms that could significantly change brain functioning in transgenic mice. They 
discussed how Depakote enhanced long-term recognition memory and spatial learning 
and memory in AD transgenic mice. Their research showed that Depakote could 
significantly elevate histone acetylation through HDACs activity inhibition and increase 





suggested Depakote, when serving as an HDAC inhibitor, can be considered as a 
potential psychoactive medication for the improvement of cognitive function in AD. 
Furthermore, this research points up the gap in and need for research on the impact of 
Depakote on STM in NH dementia residents, as existing studies continue to yield 
inconsistent results. 
Summary and Conclusions 
 This chapter provided a detailed account of current professional literature about 
the impact of Depakote on agitation and STM in NH dementia residents. A considerable 
number of studies have focused on various aspects of Depakote, agitation, and STM, 
including risks versus benefits, the effectiveness of psychoactive medications, and how 
the use of psychoactive medications might modify already present psychiatric symptoms. 
Depakote uses to manage BPSD in NH dementia residents was consistently reported not 
to improve agitation in dementia and to increase the frequency of side effects (Narayana 
et al., 2014). Although Depakote treatment options exist to treat agitation in NH dementia 
residents, inconsistent findings from existing research studies indicate the need for further 
research on the use of Depakote to manage agitation and aggression in BPSD in NH 
residents. Additionally, research studies considered the potential for a decline in 
cognitive function among NH residents with AD while on Depakote but did not touch 
specifically on STM in NH residents with AD. Several studies in the literature review 
conducted research addressing exposure to psychoactive medications and cognitive 





Again, due to inconsistencies in findings from the literature reviewed, there is a 
continued call for further research into the impact of Depakote on agitation and STM in 
NH dementia residents. The impact of Depakote on agitation and STM in NH residents 
with dementia remains unclear. The goal of this study was not to solve the identified 
problem but to add to the existing literature, thereby increasing knowledge on the impact 
of Depakote treatment on agitation and STM in NH dementia residents over a 1-year 
period. Chapter 3 lays the groundwork for the research design, methodology, and data 






Chapter 3: Research Method 
The purpose of this quantitative study, which included a nonexperimental design, 
was to examine the impact of Depakote on agitation and STM in NH residents with 
dementia over a 1-year period. The independent variable was Depakote treatment, and the 
dependent variables were agitation and STM. There was also a variable of interest, effect 
over time (trials). The study included a confounding variable, which was the residents’ 
original Depakote start date to test for within-subject effects.  
This chapter contains the research methods employed in this study. A brief review 
of the design and rationale of the study, including setting and sampling procedure, 
procedures for recruitment, participation and data collection, and instrumentation, is 
presented. Next, the data analysis plan is discussed, including research questions, 
hypotheses, and statistical tests. A review of the threats to external, internal, and 
construct validity, including reliability of the instrument, data assumptions, sample size, 
and the measures taken to protect residents’ rights, concludes this chapter. 
The independent variable for this study was Depakote treatment, and the 
dependent variables were agitation and STM. According to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5, 2013), agitation and memory loss are two 
symptoms of dementia. Resident behaviors, psychological symptoms, and cognition were 
examined to determine whether Depakote use impacted agitation and STM. The residents 
in this study were required to have a diagnosis of dementia and be prescribed Depakote 





treat seizure disorder were excluded from this study (FDA, 2010). All data for this study 
were archived data from an existing dataset, and there was no direct communication 
between me and the residents. 
This chapter presents a detailed description of the methodology used in this study 
to facilitate replication by other researchers. The major sections include the sampling and 
sampling procedures along with all procedures of recruitment, participation, and data 
collection. Next, I describe the instrument and operationalization constructs including the 
developers, appropriateness to this study, and reliability and validity. Additionally, 
threats to validity such as external, internal, and construct validity are presented. Finally, 
ethical procedures and concerns related to this study are described.  
Research Design and Rationale 
 This quantitative study included a nonexperimental design. Data for sample 
selection were collected data using consulting pharmacy records. Data were then 
measured by MDS assessment results to determine whether Depakote use affected levels 
of agitation and STM in NH dementia residents over a 1-year period. 
 I used a quantitative approach including a repeated-measures within-subjects 
ANOVA to analyze data from two archived databases containing NH residents receiving 
Depakote. Because the purpose of this study was to determine whether Depakote 
impacted levels of agitation and STM over a 1-year period, a repeated-measures within-
subject (effect over time) design was appropriate for this study. The repeated-measures 





archived data were measured on each variable. The null hypothesis stated there are no 
statistically significant differences in levels of agitation or STM in the Depakote 
treatment group over a 1-year period. The alternative hypothesis stated there are 
statistically significant differences in levels of agitation and STM in the Depakote 
treatment group over a 1-year period. 
 Because I used archival data from two existing data sets, I did not have direct 
contact with the residents, which mitigated ethical issues related to vulnerable 
populations and cognitively impaired residents. Data were gathered from the consulting 
pharmacies’ database and two NHs MDS records to measure the impact of Depakote use 
on agitation and STM in NH dementia residents. This system of data gathering ensured 
the diagnosis of dementia, prior behaviors, current behaviors, and resident receipt of 
Depakote over the 1-year period. MDS is a tool mandated for use in NHs for clinical 
assessments of all residents on Medicare and Medicaid. The MDS provides a 
comprehensive assessment of each resident’s functional capabilities, health-related 
issues, behaviors, psychological symptoms, and cognitive function. 
Methodology 
Population 
 The target population for this study was dementia residents from two local NHs. 
The residents for this study consisted of NH dementia residents receiving Depakote 
treatment for BPSD from January 1, 2016, through December 31, 2016, because this was 





Sampling and Sampling Procedures 
 Purposive sampling was used for this study because the NH sample was being 
sampled with a specific purpose (specific to NH residents on Depakote and its impact on 
agitation and STM; see Frankfort-Nachmias, Nachmias, & DeWaard, 2015). Purposive 
sampling is a nonprobability technique that was used based on characteristics of the NH 
dementia residents (population) and Depakote treatment (objective). This sampling 
strategy was suitable for this study’s research questions and variables addressing the 
extent to which Depakote impacts agitation and STM in NH dementia residents over a 1-
year period.  
 The sample for this study was obtained from archival data collected from January 
1, 2016, through December 31, 2016, by the consulting pharmacy and the NHs MDSs. 
The procedure for drawing the sample involved various steps. First, all residents were 
from the two local NHs and were receiving Depakote for BPSD. Second, the consulting 
pharmacy records were provided with deidentified data including psychoactive 
medications, the reason for Depakote prescription, Depakote dosage, and the start date of 
Depakote administration. Residents receiving Depakote for any reason other than 
agitation/behaviors related to dementia were excluded. Also, residents were required to 
be on Depakote for the entire 1-year period. Third, MDS records were obtained through 
the NHs. MDS records included deidentified data including date of birth, gender, and 
Sections C (Cognitive) and E (Behavioral) of the MDS. The consulting pharmacy and 





agreements between the data providers and me ensured protection and confidentiality of 
resident information. 
 The study’s sampling frame was the group of residents from two local NHs that 
met eligibility criteria for selection. More specifically, the sampling frame was the 
consulting pharmacy list of NH residents receiving Depakote, comprising the sample 
selection of MDSs from the two NHs (permission granted through data agreements 
between the data providers and me). Only residents on Depakote for behaviors/agitation 
from that list met study selection criteria. Any NH resident on Depakote for any other 
reason other than BPSD was excluded from the study because the study was specific to 
dementia residents. Moreover, only selected data collected from those residents who had 
been receiving Depakote for the entire 1-year period were used. Gender, race, and age 
were not examined in this study because of the smaller sample size.  
 The sample size of a study is determined before research begins as an effort to 
ensure a sufficient number of responses (Creswell, 2014). Having a sufficient sample size 
ensures enough data (Creswell, 2014). I used G*Power 3.1 (see Faul, Erdfelder, Buchner, 
& Lang, 2009) to calculate sample size for a one-way repeated-measures ANOVA. When 
a population is of limited size, Cohen (1982) stated it is appropriate to set the alpha at .10 
or higher, and Stevens (2002) stated a priori power should be at least .70. With four 
repeated measures correlated at .50, a medium-size population effect size of Cohen’s f = 
.25 would be detectable with a sample size of 15, and an even smaller effect size of 





Procedures for Recruitment, Participation, and Data Collection 
Resident data were data archived from January 1, 2016, to December 31, 2016, 
from two local NHs. At the beginning of this research process, I contacted both NH 
administrators face-to-face to introduce the study, explain the purpose of the study, and 
request use of residents’ MDS archival data. Immediate approval was given by both NH 
administrators at that time to obtain residents’ MDS data for this study. Next, I contacted 
the pharmacy consultant via e-mail to introduce the study. I explained the purpose of the 
study and requested archival data (i.e., residents on Depakote, Depakote administration 
start and end dates, the reason for Depakote use, gender, and date of birth). The pharmacy 
consultant agreed to provide the requested data for this study. 
 The data collection for the main dataset required the consulting pharmacy to 
provide data from residents of two local NHs who are on Depakote treatment for BPSD. 
The consulting pharmacy has proprietary rights to all the de-identified information that 
was provided. The procedure for gaining access to the data set involved a data use 
agreement between the data provider (consulting pharmacy) and the data recipient (me), 
which permitted limited use of the de-identified data set for research purposes only. The 
data use agreement (Appendix A) with the consulting pharmacy specified access to a 
limited deidentified data set (i.e., date of birth, gender, psychoactive medications, the 






 Collection of secondary data involved administrators and MDS coordinators from 
both participating NHs. NH administrators authorized NH MDS coordinators to give 
access to MDS records of study residents from the main data set. NH MDS coordinators 
provided copies of study residents’ Sections C (Cognitive) and E (Behavioral) of the 
MDS (deidentified dataset). NHs have the sole rights to all MDS records needed for this 
study; therefore, resident permission was not needed. The procedure for gaining access to 
the data set involved a data use agreement similar to the agreement with the consulting 
pharmacy. The data use agreement was between the data provider (NH) and data 
recipient (me), which permitted limited use of the de-identified data set for research 
purposes only. The data use agreement with the NHs specified a limited data set (i.e., 
date of birth, gender, and Sections C [Cognitive] and E [Behavioral] of the MDS).  
 Use of the data sets was granted from the consulting pharmacy and the two local 
NHs (i.e., the owners of the confidential data being provided to me). All residents had a 
diagnosis of dementia and were not able to provide consent; therefore, the NHs had the 
right to determine the utility of sharing the data for research purposes. Residents were 
identified by ID 1-16, and NH names remained confidential to protect all information 






Instrumentation and Operationalization of Constructs 
Minimum Data Set (MDS) 
The MDS is a standardized tool for assessment and facilitation of care 
management in NHs developed by U.S. Centers for Medicare & Medicaid Services 
(CMS; CMS.gov, 2015). The MDS is a care management tool used in NHs and is a set of 
screening and assessment tools that are part of a Resident Assessment Instrument (Cirillo, 
2017). The MDS provides an assessment of NH residents’ functional capabilities and 
helps identify problem areas. The MDS is performed on every resident in Medicare 
and/or Medicaid-certified long-term care facilities.  
 The MDS is designed to be reliable and accurate and to include the resident (if 
cognitively able) in the assessment process. CMS (2015) reported that enhanced accuracy 
of the MDS supports the intent that MDS be a tool to improve clinical assessment and 
support the credibility of programs that rely on MDS. The MDS includes frequency 
reports designed to summarize each NH resident’s information, creating an MDS 
assessment record. The MDS assessment information for each NH resident is 
consolidated to create a profile of the most current standard information for the resident. 
A detailed copy of Sections C (Cognitive) and E (Behavioral) of the MDS is located in 
Appendix D.  
 The MDS is structured by sections A-Q, V, X, and Z, including a title and intent 
for each section. Each section provides instructions on how to complete the section. The 





Section titles are as follows: Identification Information (A), Hearing, Speech, and Vision 
(B), Cognitive Patterns (C), Mood, Behavior (D), Preferences for Customary Routine and 
Activities (F), Functional Status (G), Bladder and Bowel (H), Active Disease Diagnosis 
(I), Health Conditions (J), Swallowing/Nutritional Status (K), Oral/Dental Status (L), 
Skin Conditions (M), Medications (N), Special Treatments and Procedures (O), 
Restraints (P), Participation in Assessment and Goal Setting (Q), Care Area Assessment 
(CAA) Summary (V), Correction Request (X), Assessment Administration (Z). 
 An example is from Section C, Cognitive Patterns. This area begins with C0100: 
Should Brief Interview for Mental Status (C0200-C0500) be conducted? This interview 
should be attempted with all residents. This area is coded as follows: (0) No (resident is 
rarely/never understood)–Skip to and complete C0700-C1000, Staff Assessment for 
Mental Status, (1) Yes–Continue to C0200, Repetition of Three Words. For example, if 
the response were coded 1, the next section would be Brief Interview for Mental Status 
(BIMS) (C0200) Repetition of Three Words. The resident is asked to repeat three words, 
for example, sock, blue, and bed. This area is coded by the number of words repeated 
after the first attempt: (0) None, (1) One, (2) Two, (3) Three. After the resident’s first 
attempt, the examiner repeats the words using cues such as sock, something you wear; 
blue, a color; bed, a piece of furniture, and these words may be repeated up to two more 
times. Followed by Temporal Orientation (C0300) (orientation to year, month, and day). 
(A) Able to report correct year is coded (0) Missed by > 5 years or no answer, (1) Missed 





(0) Missed by >1 month or no answer, (1) Missed by 6 days to a month, (2) Accurate 
within 5 days; (C) Able to report correct day of the week is coded (0) Incorrect or no 
answer, (1) Correct (CMS.gov, 2015). Followed by Recall (C0400) (Ask resident to 
repeat the three words asked earlier). (A) Able to recall “sock”, (B) Able to recall “blue,” 
(C) Able to recall “bed,” all coded using (0) No, could not recall, (1) Yes, after cueing, 
(2) Yes, no cue required (CMS.gov, 2015). 
 At this point in the assessment, scores are added up from sections C0200-C0400, 
ranging from 00-15 (15 being the most cognitively intact). The assessor would enter 99 if 
the resident was unable to complete the interview.  
 If the resident was unable to complete the interview, a staff assessment is 
completed. This area begins with C0600, Should Staff Assessment for Mental Status be 
Conducted? This area is coded (0) No (resident was able to complete interview) Skip to 
C1300, Signs, and Symptoms of Delirium, (1) Yes (resident was unable to complete 
interview) Continue to C0700, Short-term Memory OK. Staff Assessment for Mental 
Status (C0700) Short-term Memory OK (seems or appears to recall after 5 minutes) is 
coded (0) Memory OK, (1) Memory problem, (C0800) Long-term Memory OK (Seems 
or appears to recall long past) is coded (0) Memory OK, (1) Memory problem, (C0900) 
Memory/Recall Ability (check all that resident was normally able to recall) is coded (A) 
Current season, (B) Location of own room, (C) Staff names and faces, (D) That he or she 
is in a nursing home, (Z) None of the above were recalled. Followed by Cognitive Skills 





coded (0) Independent—decisions consistent/reasonable, (1) Modified independence—
some difficulty in new situations only, (2) Moderately impaired—decisions poor; 
cues/supervision required, (3) Severely impaired—never/rarely made decisions 
(CMS.gov, 2015).  
The next area is Delirium (C1300) Signs and Symptoms of Delirium. (A) 
Inattention, (B) Disorganized thinking, (C) Altered level of consciousness, (D) 
Psychomotor retardation, all of which are coded using (0) Behavior not present, (1) 
Behavior continuously present, does not fluctuate, (2) Behavior present, fluctuates 
(comes and goes, changes in severity). Lastly in the cognitive section, is Acute Onset 
Mental Status Change (C1600), Is there evidence of an acute change in mental status 
from the resident’s baseline?. This area is coded (0) No, (1) Yes (CMS.gov, 2015). 
Another example is from Section E, Behavior, (E0100) Psychosis (Check all that 
apply) (A) Hallucinations (perceptual experiences in the absence of real external sensory 
stimuli), (B) Delusions (misconceptions or beliefs that are firmly held, contrary to 
reality), (Z) None of the above. Followed by Behavioral Symptom—Presence and 
Frequency (E0200), (A) Physical, behavioral symptoms directed toward others (hitting, 
kicking, pushing, scratching, grabbing, abusing others sexually), (B) Verbal behavioral 
symptoms directed toward others (threatening others, screaming at others, cursing at 
others), (C) Other behavioral symptoms not directed toward others (physical symptoms 
such as hitting or scratching self, pacing, rummaging, public sexual acts, disrobing in 





screaming, disruptive sounds). This area is coded using the following: (0) Behavior not 
exhibited, (1) Behavior of this type occurred 1 to 3 days, (2) Behavior of this type 
occurred 4 to 6 days, but less than daily, (3) Behavior of this type occurred daily. Overall 
Presence of Behavioral Symptoms (E0300), Were any behavioral symptoms in questions 
E0200 coded 1, 2, or 3? (0) No—skip to E0800, Rejection of care, (1) Yes—Considering 
all of E0200, Behavioral Symptoms, answer E0500 and E0600. Impact on Resident 
(E0500), Did any of the identifying symptom(s): (A) Put the resident at significant risk 
for physical illness or injury, (B) Significantly interfere with the resident’s care, (C) 
Significantly interfere with the resident’s participation in activities or social interactions, 
all coded with (0) No or (1) Yes. Impact on others, (E0600), Did any of the identifying 
symptom(s): (A) Put others at significant risk for injury, (B) Significantly intrude on the 
privacy or activities of others, (C) Significantly disrupt care or living environment, all 
coded with (0) No or (1) Yes (CMS.gov, 2015).  
Rejection of Care—Presence and Frequency (E0800), Did the resident reject 
evaluation or care (bloodwork, taking medications, ADL assistance) that is necessary to 
achieve the resident’s goals for health and well-being (excluding already addressed 
behaviors): (0) Behavior not exhibited, (1) Behavior of this type occurred 1 to 3 days, (2) 
Behavior of this type occurred 4 to 6 days, but less than daily, (3) Behavior of this type 
occurred daily (CMS.gov, 2015).  
Wandering—Presence and Frequency (E0900), Has the resident wandered: (0) 





this type occurred 4 to 6 days, but not daily, (3) Behavior of this type occurred daily. 
Wandering—Impact (E1000): (A) Does the wandering place the resident at significant of 
getting to a potentially dangerous place (stairs, outside of the facility), (B) Does the 
wandering significantly intrude on the privacy or activities of others, all coded (0) No or 
(1) Yes. Finally, to sum up the behavior section E, Changes in Behavior or Other 
Symptoms (E1100), How does resident’s current behavior status, care rejection, or 
wandering compare to prior assessment, coded as (0) Same, (1) Improved, (2) Worse, (3) 
N/A because no prior MDS assessment (CMS.gov, 2015).  
The MDS includes reports for statistical and comparison purposes, such as 
Facility Characteristics Report, Facility Level Quality Measure Report, Resident Level 
Quality Measure Report, Monthly Comparison Report, and Quality Measures Reports 
versus Nursing Home Compare. These reports provide NHs with the statistical data 
gathered from their facilities as well as facilities in their same state and other states for 
comparison purposes. For example, when an NH is rated by a number of stars, the MDS 
reports will provide the NH with knowledge of the areas that their facility lacks in 
compared to other facilities. This will help improve quality of care. Also, the MDS 
reports specify areas for improvement. Tucker (2013) reported that research over the past 
four years, since the MDS was restructured, has shown an increase in reliability and 
validity, specifically inaccuracy of the mood and cognitive status sections. One of the 





and/or direct care staff in the assessments, which provides more accurate and valid 
responses. 
Data Analysis Plan 
This study was conducted using R statistical software version 3.3.1 to examine to 
what extent Depakote affects levels of agitation and STM in NH dementia residents over 
a 1-year period. These variables were measured using the consulting pharmacy’s records 
and two NH MDS records in four intervals over a 1-year period and imputed into R 
statistical software for statistical analysis. A repeated measures ANOVA was used to 
analyze data in R statistical software. Additionally, boxplots were done to examine if the 
length of time the resident was on Depakote had any significance on resident’s agitation 
and STM scores. 
Restatement of the Research Questions and Hypotheses  
RQ1: To what extent does Depakote treatment affect levels of agitation in NH 
dementia residents over a 1-year period? 
H01: There is not a statistically significant difference in levels of agitation with 
Depakote treatment over a 1-year period as evidenced by no change in agitation from 
preexisting data in Section E of the MDS. 
Ha1: There is a statistically significant difference in levels of agitation with 
Depakote treatment over a 1-year period as evidenced by decreased agitation from 





RQ2: To what extent does Depakote treatment affect STM in NH dementia 
residents over a 1-year period? 
H02: There is not a statistically significant difference in STM with Depakote 
treatment over a 1-year period as evidenced by no change in STM functioning from 
preexisting data in Section C of the MDS. 
Ha2: There is a statistically significant difference in STM with Depakote 
treatment over a 1-year period as evidenced by decreased STM functioning from 
preexisting data in Section C of MDS. 
Statistical Testing 
 This study used a repeated measures ANOVA statistical test that screens for 
multiple measures from a group of people (Frankfort-Nachmias, Nachmias, DeWaard, 
2015). A repeated measures ANOVA is used when there are multiple dependent 
variables, and the researcher is looking for differences amongst treatment groups. 
Therefore, since this study consisted of two dependent variables (agitation and STM), one 
independent variable (Depakote treatment group), and repeated measures within factor 
(effect over time) using four intervals over a 1-year period, the data were screened using 
a repeated measures ANOVA to test the null and alternative hypotheses. Hence, the 
ANOVA statistical analysis was appropriate to examine to what extent Depakote affected 
levels of agitation and STM in the Depakote treatment group. Additionally, ANOVA was 
used to consider a within factor effect over time, which was pertinent to testing this 





confounding variable, which was the residents’ original Depakote start date, to test for 
within-subject random effects. Hence, box plots were employed for comparison of a 
number of months the resident was on Depakote before the study. Further, the results of 
this study were interpreted using certain key parameter estimates. 
Threats to Statistical Conclusion and Validity 
External Validity 
 External validity refers to a generalization of the treatment outcomes. For 
example, the external validity in this study related to repeated measures as it is difficult to 
control for the effects of prior outcomes using the same subject (Frankfort-Nachmias, 
Nachmias, & DeWaard, 2015). A repeated measures ANOVA was used for this study 
because it allows both dependent variables to be measured on the same independent 
variable. Also, this study had a within-subject variable of interest (effect over time) to 
examine if the residents changed from the first trial to final trial, which minimized threats 
to external validity. No pretest was conducted which could have potentially influenced 
the residents’ responsiveness or sensitivity to the experimental variable (Creswell, 2014), 
thereby resulting in no threats to a reactive or interaction effect of testing for this study. 
Also, there were no threats of multiple treatment interferences (no multiple treatments 
will be given to the same subject). Reactive effects of experimental arrangements for 






 The internal validity of a study refers to whether results of the study can be used 
to determine (a) if treatment makes a difference or not and (b) if there is sufficient 
evidence to support the claim (Creswell, 2014; Frankfort-Nachmias, Nachmias, & 
DeWaard, 2015). In this study, a repeated measures ANOVA was used to determine the 
impact of Depakote on agitation and STM. There was a possibility this design could 
increase the chances of internal validity by testing both dependent variables (representing 
different measurements) against the same independent variable. However, there are 
always factors that can jeopardize internal validity. For example, if the scorer of the MDS 
changes, there is a possibility of outcome changes. Furthermore, about the threats above 
to internal validity, the instrument (MDS) for this study was designed to be a reliable tool 
for clinical assessments (CMS.gov, 2015).  
Construct Validity 
 Construct validity refers to how well a test or tool measures the theorized 
psychological construct it was designed to measure (Cronbach & Meehl, 1955). The tool 
used in this study, the MDS, was designed to measure agitation/behaviors and cognition. 
This study was not exposed to construct validity, such as hypothesis guessing by 
residents, bias experimental design, and researcher expectations (secondary data was 
used; Cronbach & Meehl, 1955). However, this study may have been exposed to a threat 
to the construct validity in that it was difficult (a) to establish disease-specific actions and 





underlying pathological process or as a consequence of being in an altered state 
(Moncrieff & Cohen, 2009). Those above was identified in the limitation section. This 
potential limitation is an area for further research. 
Ethical Procedures 
Protection of Residents’ Rights 
 Ethical behaviors and protection of this studies residents are a serious matter for 
psychological studies. Every action in this study was taken with careful consideration for 
the residents. Agreement to gain access to the consulting pharmacists’ data was received 
by way of a formal data use agreement (see Appendix A). The agreement was signed by 
both the data provider and data recipient to permit the usage of the dataset from the 
consulting pharmacist. The agreement was limited to the resident’s gender, date of birth, 
psychoactive medications, the reason for Depakote prescription, Depakote dosage level, 
and the start date of Depakote. The contract excluded all medications other than 
psychoactive medications. A detailed copy of the data use agreement contract is located 
in Appendix A. 
 Access to the NHs MDS records was gained by way of formal data use 
agreements (see Appendices B and C). The agreements were signed by both NHs (data 
providers) and the data recipient to permit usage of the MDS dataset. The agreements 
were limited to the resident’s date of birth, gender, and Sections C (Cognitive) and E 
(Behavioral) of the MDS. The contracts excluded all identifying information. Detailed 





 This study did not involve any interactions with or observations of human 
subjects. Permission was gained from the Institutional Review Board (IRB) by 
completing an application to ensure that the ethical principles of beneficence, justice, and 
respect for persons were upheld in this study. In this study, secondary data were used, 
thereby limiting ethical concerns related to recruitment materials and processes as well as 
data collection. In the collection of the original data, the collectors of the data, the 
consulting pharmacist and two local NHs, ensured that residents were treated fairly. 
Confidentiality and limits to confidentiality were discussed and guaranteed in the original 
data collection process. Furthermore, families of the residents were involved in making a 
choice regarding psychoactive medications, including risks and benefits. There were no 
reports of families declining the administration of psychoactive medications or any 
adverse events that occurred during the original data collection process. There was also 
no report of any resident’s Depakote being discontinued during the 1-year study period. 
 Data are confidential as stated in the resident’s initial paperwork upon admission 
to the NHs. Before starting psychoactive medications, the NHs notify the resident and/or 
families of their consent. There have been no breaches of confidentiality or concerns 
about this data set.  
 The pharmacy consultant and the NHs abide by strict measures to preserve the 
confidentiality of the data. The procedure involved no access to data from the pharmacy 
consultant other than for the NHs purpose. The pharmacy consultant stored resident data 





confidentiality of the data. MDSs are stored on computers of clinical staff that complete 
them, in the MDS 3.0 software program. Both data providers back data up on discs for 
safety purposes in the event that computers crash.  
 The data dissemination of the pharmacy consultant was limited to himself, both 
NHs, and the pharmacy that dispenses the medications. The data dissemination of the NH 
MDS’s was limited to the NHs, insurance companies (for payment purposes), and the 
New York State Department of Health (NYSDOH) to ensure proper completion and 
adherence. The residents and/or families were not recipients of the reports or data. In 
compliance with NYSDOH guidelines, an NH resident’s data are held for seven years 
following the resident’s death.  
 Hard copies of data received from the pharmacy consultant and the NHs are 
secure in a locked fireproof box, and the researcher is the only person with access to that 
locked box. The raw data were coded into R statistical software for statistical analysis, 
using my personally secured (administrator password-protected) computer equipped with 
Webroot antivirus software and anti-spyware protection. Following analysis, statistical 
data were then securely stored on a separate hard drive with restricted access by 
administrator password protection. Also, write permission was disabled to prevent 
altering of the data so that they remained safe. Antivirus and anti-spyware were run on a 
daily basis and updates were applied to maintain the security of the data set. Lastly, the 
data will be kept for five years as required by Walden University, and copies will be 





the data will be securely shredded and disposed of, and electronic files will be erased 
from computers. 
 There are no other ethical issues related to this study. Using secondary data 
eliminated the ethical risk of conducting the study at my internship site, eliminating 
conflicts of interest in this study. Also, use of secondary data protects both the vulnerable 
population (geriatric NH residents) and me from ethical risks. 
Summary 
 This chapter included justification for the research design and rationale for my use 
of a quantitative approach with repeated measures within-subject design to analyze 
archival data. The rationale for the use of a repeated measures ANOVA was discussed. It 
was agreed that a repeated measures design for this study facilitated testing the 
hypotheses of whether or not there is a statistically significant difference in levels of 
agitation and STM with Depakote treatment over a 1-year period. Moreover, effect over 
time was a variable of interest that measured if the residents changed from the first trial to 
the final trial. The methodology, including the target population (local NH dementia 
residents) sampling strategy (purposive sampling), procedures, sampling frame, and 
power analysis were used to determine sample size and discussed in depth to ensure that 
this study was replicable. Next, the data collection procedures of the archival data along 
with the published instrument (MDS) were presented. Further, the threats to the study’s 
external, internal, and construct validity were examined, as well as how these threats 





what data will be included in the data set provided), treatment of human residents (with 
beneficence, justice, and respect), and treatment of data (with confidentiality maintained 
and protected) were examined and addressed. The subsequent chapter will explore the 







Chapter 4: Results 
The purpose of this nonexperimental quantitative study was to examine the 
impact of Depakote on agitation and STM in NH dementia residents over a 1-year period. 
This study was conducted to answer two research questions: 
1. To what extent does Depakote treatment affect levels of agitation in NH 
dementia residents over a 1-year period? 
2. To what extent does Depakote treatment affect STM in NH dementia 
residents over a 1-year period? 
The first null hypothesis stated no statistically significant difference in levels of agitation 
with Depakote treatment over a 1-year period as evidenced by no change in agitation 
from preexisting data in Section E of the MDS. The second hypothesis stated no 
statistically significant difference in STM with Depakote treatment over a 1-year period 
as evidenced by no change in STM functioning from preexisting data in Section C of the 
MDS. The hypotheses were tested using repeated-measures ANOVA. This chapter 
presents the method for collecting data and the results of the data analysis to address the 
research questions and hypotheses. First, I provide the details of the data collection, 
including descriptive statistics of the sample. Then I present the results of the data 





Data Collection and Characteristics of the Sample 
Data Collection 
NH residents with dementia and agitation who were receiving Depakote over the 
1-year period were the sample for this study. A total of 16 residents from the two NHs 
were used for the sample. Two NHs were necessary to obtain the required sample size 
based on selection criteria that residents had been on Depakote for the 1-year period, had 
been diagnosed with dementia, had been prescribed Depakote to treat agitation, had not 
been prescribed Depakote for other diagnoses. A sample from one facility was too small 
for the study, and a second facility was needed. There were no variations between the two 
NH MDS data sets because both NH MDS coordinators were expected to follow the same 
MDS completion requirements. Demographics were not included in this study because 
the sample was too small for demographics to be significant (see Cohen, 1982). Data 
from the consulting pharmacy providing residents who met the study criteria were sent 
via secured e-mail to the participating NH data providers following IRB approval. I 
obtained study data within three days of the NH receiving the data from the consulting 
pharmacy. I physically acquired all residents’ MDSs from the data providers, which 
included four separate MDSs per resident for repeated measures during the study period. 
This data collection process went as proposed and there were no discrepancies.  
Characteristics of Sample  
All residents were residents at one of the two participating NHs, had a diagnosis 





dates varied from 2013 through 2016, but they were all receiving Depakote from January 
2016 through December 2016, which was the period evaluated. Each resident had four 
measures of agitation and STM scores over the 1-year period. Possible behavior/agitation 
scores ranged from 0 to 3, 0 indicating no behavior exhibited, 1 indicating behavior 
occurred 1 to 3 days, 2 indicating behavior occurred 4 to 6 days (but less than daily), and 
3 indicating behavior occurred daily. From the 16 residents (labeled as ID), 11 scored 0 
on all four behavior measures; three scored three 0’s and one 2 on the four measures; one 
scored two 0’s and two 2’s on the four measures; one scored three 0’s and one 3 on the 
four measures. Agitation scores are shown in Table 1.  
Regarding STM, possible scores are 00-15 (15 indicating the most cognitively 
intact). STM was measured four times over the 1-year period. Some residents’ STM 
varied slightly and others’ more significantly over the 1-year period. STM scores are 







Characteristics of the Study Sample 
ID Time Depakote start 
date 
Agitation STM score 
1 1 1/31/13 0 07 
1 2  0 02 
1 3  0 04 
1 4  2 00 
2 1 5/321/15 0 08 
2 2  0 00 
2 3  0 00 
2 4  0 00 
3 1 1/30/16 0 09 
3 2  0 14 
3 3  0 14 
3 4  0 15 
4 1 10/25/14 0 00 
4 2  2 00 
4 3  0 00 
4 4  0 00 
5 1 12/27/15 0 14 
5 2  0 12 
5 3  0 10 
5 4  0 10 
6 1 5/31/15 2 13 
6 2  0 15 
6 3  0 14 
6 4  0 14 
7 1 2/22/14 0 06 
7 2  0 07 
7 3  0 07 
7 4  0 07 
8 1 7/26/13 0 00 
8 2  0 00 
8 3  0 00 
8 4  0 00 








ID Time Depakote Start 
Date 
Agitation STM Score 
9 2  0 15 
9 3  0 15 
9 4  0 12 
10 1 5/31/15 0 00 
10 2  0 00 
10 3  0 01 
10 4  0 00 
11 1 1/23/16 0 00 
11 2  2 13 
11 3  2 13 
11 4  0 15 
12 1 7/29/13 0 05 
12 2  0 06 
12 3  0 12 
12 4  0 04 
13 1 10/24/15 0 14 
13 2  0 14 
13 3  0 12 
13 4  0 13 
14 1 10/25/14 0 15 
14 2  0 15 
14 3  0 15 
14 4  3 15 
15 1 6/28/15 0 11 
15 2  0 11 
15 3  0 06 
15 4  0 11 
16 1 7/19/13 0 00 
16 2  0 00 
16 3  0 00 








Before data analysis, data were screened to ensure residents met selection criteria. 
The consulting pharmacy provided the two NHs with data from the residents who met 
study criteria. Study criteria were as follows: residents had to be on Depakote for the 1-
year period, had to have a diagnosis of dementia, and had to be prescribed Depakote to 
treat agitation, Residents on Depakote for other diagnoses were excluded. This allowed 
the NHs to provide me with a final deidentified data set that included 16 residents with a 
diagnosis of dementia who were receiving Depakote for agitation for the 1-year period 
addressed in this study. The MDS was the tool used for assessment measures, and four 
quarterly MDSs per resident were provided for repeated-measures ANOVA with within-
subject effects.  
Overview of Design and Procedures  
Agitation and STM were assessed for each resident through archival data from the 
pharmacy consultant and the two NHs. The MDS was the instrument used by the NHs for 
initial assessments, and MDS data were provided to me for analysis. The MDS was used 
to determine the resident’s agitation and cognitive scores over a 1-year period. The 
sections of the MDS that were used to measure the resident’s agitation and cognition 
scores were Section C (Cognition) and Section E (Behavior). The agitation scores ranged 
from 0 to 3. Out of the 64 repeated measures, there were five scores of 2, one score of 3, 
and 58 scores of 0. The STM scores ranged from 00 to 15 and varied from resident to 





were 7.5 and 6.10. The mean scores and standard deviations for the dependent variables 
are shown in Table 2. 
Table 2 
Descriptive Statistics for Agitation and STM  
Variable Mean SD 
Agitation 0.20 0.65 
         
              STM 
           





Data Analysis Results and Major Findings 
To test the hypotheses and examine the impact of Depakote on agitation and STM 
in NH dementia residents over a 1-year period, I conducted a repeated-measures within-
subjects ANOVA; however; because of possible correlation within the subjects, I 
employed boxplots to determine whether the length of time residents were on Depakote 
had any significance. Data were analyzed using R Statistical Software Version 3.3.1 for 
Windows or Mac. Preliminary tests were done on the data before running the repeated-
measures ANOVA. Simple plots and boxplots were employed to get an overall view of 
the data before proceeding to more complex analyses using repeated-measures ANOVA. 
The simple plots in Figure 1 and Figure 2 showed no clear increasing or decreasing 





























To simplify the data, I used boxplots with differences between time intervals. The 
boxplots in Figure 3 and Figure 4 indicated no difference between the scores after another 
























To rule out the effect of varying Depakote start dates; the differences in scores 
over time were compared to the number of months from the Depakote start date to the 
start of the study. The boxplots in Figure 5 and Figure 6 show there was no clear 
























Figure 6. Boxplots for differences in STM scores compared to Depakote start date.  
 
Repeated measures ANOVA was used to test the difference in agitation over the 
1-year period of Depakote treatment. A typical rule-of-thumb for ANOVA is to reject the 
null when the p-value is below 0.05. Under this cut-off, there was no significant evidence 
to reject the null hypothesis H01 for agitation (F-value 0.07, p-value = 0.7988) and STM 
scores (F-value 0.0023, p-value = 0.9617). 
A further ANOVA test was done to examine if repeated measures ANOVA was 
required with this data set. Accounting for the random effects of ID is the main difference 
between an ANOVA and a repeated measures ANOVA. In this test, the ANOVA was 
used to check if there was a significant difference model with or without the random 
effects of ID. There was no significant difference between with and without random 
effects models for agitation (df=3, p-value = 0.2266), however, there was a significant 





(df =3, p-value < 0.0001). A repeated measures ANOVA was required for STM scores; 
the repeated measures ANOVA still did not show a significant difference in STM scores 
over time. 
Research Question 1  
To what extent does Depakote treatment affect levels of agitation in NH dementia 
residents over a 1-year period? 
H01: There is not a statistically significant difference in levels of agitation with 
Depakote treatment over a 1-year period as evidenced by no change in agitation from 
preexisting data in Section E of the MDS. 
Ha1: There is a statistically significant difference in levels of agitation with 
Depakote treatment over a 1-year period as evidenced by decreased agitation from 
preexisting data in Section E of MDS. 
The repeated measures ANOVA found no significant difference (F = 4.96, df = 
(3), p = 0.2266) between agitation and Depakote treatment over the 1-year period; 
therefore, there was no significant evidence to reject the null hypothesis.  
Research Question 2 
To what extent does Depakote treatment affect STM in NH dementia residents 
over a 1-year period? 
H02: There is not a statistically significant difference in STM with Depakote 
treatment over a 1-year period as evidenced by no change in STM functioning from 





Ha2: There is a statistically significant difference in STM with Depakote 
treatment over a 1-year period as evidenced by decreased STM functioning from 
preexisting data in Section C of MDS. 
The repeated measures ANOVA found no significant difference (F = 26.95, df = 
(3), p = <.0001) between STM and Depakote treatment over the 1-year period; therefore, 
there was no significant evidence to reject the null hypothesis. 
Exploratory Analysis of Length of Time on Depakote and Agitation and STM 
Although the length of time on Depakote was not used in any of the primary 
analyses, it is possible that the effects of length of time on Depakote can impact agitation 
and STM scores. Specifically, it might be that a resident who has been on Depakote 
treatment for a longer period may have lower agitation scores and higher STM scores. 
However, boxplots did not show any clear correlation between length of time on 
Depakote and agitation scores. Though findings did show significant differences in the 
exploratory analysis of STM scores and length of time on Depakote, results were still not 
significant over the 1-year study period.  
Summary 
Based on the findings of these analyses, the null hypothesis could not be rejected 
for the two research questions explored, which examined the impact of Depakote on 
agitation and STM in NH dementia residents over a 1-year period. Reported findings 





Additionally, with random effects, there was still no significant difference in agitation 
scores.  
Findings did not support the hypotheses that there were significant differences in 
STM scores in NH dementia residents on Depakote over a 1-year period. Although 
findings did show significant differences in the exploratory analysis of STM and length 
of time on Depakote, results were still not significant over the 1-year study period. 
Chapter 5 will include a summary of this study and an explanation of why and how the 
study was conducted. Conclusions based on the results and impacts of these conclusions 
will be presented. Implications of this study will be discussed, along with 






Chapter 5: Discussion, Conclusion, and Recommendations 
Study Overview 
The purpose of this nonexperimental study was to examine the impact of 
Depakote on agitation and STM in NH dementia residents over a 1-year period. Despite 
the vast amount of literature on Depakote used for agitation and its effects on cognition, 
the existing studies indicated inconsistent results. Results of the current study indicated 
no significant impact of Depakote on agitation and STM scores. Although the length of 
time on Depakote was not addressed in primary analyses, testing of IDs with and without 
random effects for agitation indicated no significant differences. The current study 
findings revealed significant improvement in the model when accounting for random 
effects of ID for STM scores, but no significant difference in the repeated-measures 
ANOVA in STM scores was found over the 1-year period.  
The importance of this study was justified by the dearth of empirical data 
regarding Depakote’s impact on agitation and STM in NH dementia residents. The use of 
Depakote and its impact on NH dementia residents was well documented in the literature. 
However, because of the inconsistent findings in the literature on Depakote’s impact on 
agitation and STM in NH dementia residents, this study was needed to clarify the impact 
and efficacy of a common yet largely unexamined invasive treatment on an underserved, 
vulnerable population. This chapter includes the purpose of the study, the research 





theoretical framework. I also describe the limitations of the study, recommendations for 
further research, and implications for social change. 
Interpretation of Findings 
The data analysis was conducted to answer two research questions addressing the 
extent to which Depakote treatment affected agitation and STM in NH dementia residents 
over a 1-year period. Agitation and STM were measured using the MDS assessment 
scores. The dataset was obtained from the two participating NHs following the consulting 
pharmacies’ dataset of residents who met the study criteria.  
The initial data analysis supported the null hypothesis for Research Question 1. 
The alternative hypothesis was not accepted because results indicated that Depakote did 
not significantly affect agitation scores over the 1-year period. Even when random effects 
were accounted for, there was no significant impact. 
The second analysis also supported the null hypothesis for Research Question 2. 
The alternative hypothesis was not accepted because results indicated that Depakote did 
not affect STM scores over the 1-year period. However, when accounting for random 
effects, results showed significant improvement in STM scores. Although random effects 
analyses showed significant improvement in STM scores, results did not indicate a 
significant difference in STM scores over the 1-year period. Therefore, the null 





Literature Review and Research Findings 
This study addressed the inconsistencies in previous research findings based on 
Moncrieff and Cohen’s (2009) drug-centered theory, which purported that because 
psychoactive medications are extrinsic substances altering how the body works, there are 
advantages and disadvantages to their use that should be weighed and distinguished from 
the effects of general treatment. Depakote is an anticonvulsant medication used to 
manage agitation in approximately 80% of NH residents with dementia (Meeks & Jeste, 
2008). Medicare reports showed dementia affects approximately 5 to 8 million 
Americans, of which more than half have BPSD (Mittal et al., 2011).  
There are many different manifestations of dementia, including cognitive decline, 
alterations in mood/thought/behavior, and inability to conduct activities of daily living. 
As in the Richter et al. (2015) study, Meinhold et al. (2005) described BPSD as 
depression, hallucinations, delusions, agitation, aggression, combativeness, disinhibition, 
and hyperactivity, and found that pharmacological measures are often used to control 
BPSD. Researchers have noted that Depakote may have some advantages when used for 
agitation and aggression in dementia residents because of its lower rates of drug 
interactions and adverse effects in the dementia population. Meinhold et al. used 
pharmacy databases and MDS assessments to obtain data for residents who were 
receiving Depakote for behavior problems related to dementia. Similar to the current 
study, some exclusions were applied, such as residents who were receiving Depakote for 





dementia residents was effective, safe, and tolerable. This current study confirmed that 
Depakote use did not increase agitation scores, suggesting Depakote is effective for 
agitation.  
Herrman et al. (2007) reached findings along the same lines, reporting Depakote 
is ineffective for managing agitation in NH residents with AD and may be poorly 
tolerated in this population. Herrman et al. discussed similar previous randomized 
controlled trials that also showed no statistically significant benefits of Depakote on 
primary outcome measures, though it showed efficacy for some secondary measures. The 
major limitations of that study were the small sample size and crossover design, but 
despite these limitations, significant worsening of symptoms during Depakote treatment 
was found. Similar to the current study, no significant differences were found with 
Depakote treatment, though results showed some efficacy for secondary measures, but 
not enough to be significant. A difference between Herrman et al.’s (2007) study and the 
current study is that Herrman et al. found a significant worsening of symptoms during 
Depakote treatment, and the current study did not indicate that. The current study is also 
similar to Herrman et al.’s in that the small sample size could have impacted the results. 
STM is the system that temporarily stores and manages information that is 
necessary to complete complex cognitive tasks (Ai-Guo et al., 2015). Richter et al. (2015) 
showed that one of the adverse effects of Depakote treatment is diminished cognitive 
function. Results of the current study indicated that, when accounting for random effects 





measures ANOVA did not show a significant difference in STM scores over the 1-year 
period.  
 Dharmarajan and Gunturu (2009) discussed the high rates of AD in NH residents 
and the possible causes. Dharmarajan and Gunturu described AD as a common, acquired 
disorder that manifests as slow, progressive memory loss with at least one cognitive 
dysfunction (aphasia, apraxia, agnosia, or executive dysfunction), resulting in impaired 
occupational and social performance. Dharmarajan and Gunturu discussed (a) the use of 
psychoactive medications, including Depakote, to manage agitation and difficult 
behaviors in NH dementia residents and (b) the impact of the medication on cognitive 
function. Similar to the Richter et al. (2015) study, Dharmarajan and Gunturu addressed 
adverse effects and cognitive functioning but not specifically on STM. The current study 
did not address other adverse effects, only agitation, and STM scores because there was 
little previous research on STM and Depakote. The current study did not indicate any 
significant effect of Depakote increasing memory loss, but possibly slowing cognitive 
decline. This is because there was no significant difference in STM over the 1-year 
period, indicating IDs maintained cognitive functioning over the 1-year period. 
Ai-Guo et al. (2015) used mice to examine how astrocytes and microglia activated 
by amyloid-β (Aβ) contributed to the inflammatory process that develops around brain 
injury. Ai-Guo et al. reported that Depakote had been shown to have an anti-
inflammatory function, and their study addressed the therapeutic effect of Depakote on 





mice treated with Depakote showed markedly improved memory deficits and decreased 
Aβ deposition compared with the non-Depakote treated mice. Similar to these findings, 
results from the current study indicated no differences in STM over the 1-year period; 
therefore, there is a possibility that Depakote may contribute to the slower cognitive 
decline. In contrast, Manckoundia et al. (2008) found different results of Depakote’s 
influence on cognitive functioning. The individual in this case study showed a significant 
decline in cognitive functioning once she began the Depakote. The Depakote was then 
discontinued due to these adverse effects, and she regained her cognitive function. 
When reviewing the literature, I observed considerable inconsistencies in study 
findings. Some researchers reported that Depakote was effective for agitation, while other 
researchers reported that Depakote increased agitation and other BPSD symptoms. Some 
researchers reported that Depakote slowed cognitive decline, while other researchers 
indicated that Depakote caused a decline in cognitive functioning.  
Theoretical Framework and Research Findings  
The theoretical framework for this study was Moncrieff and Cohen’s (2009) drug-
centered theory, which suggests that because psychoactive medications are extrinsic 
substances altering how the body works, advantages and disadvantages of psychoactive 
medication use should be weighed and distinguished from the effects of general 
treatment. Drug-centered theory can inform perspectives about how psychological 
alterations produced by psychoactive medications interact with experiences of distress 





such as sedation, cognitive slowing, behaviors, altered sense of perception, sleep, and 
psychosis.  
Moncrieff and Cohen (2009) theorized that although evidence of the superiority 
of psychoactive medications might imply disease-specific effects, superior effects can 
also be explained within a drug-centered framework (e.g., the psychomotor and 
emotional restriction characteristic of psychoactive medications suppresses psychotic 
agitation more effectively than other sedatives). The drug-centered theory provides a 
useful lens through which NH resident clinicians or staff members can evaluate and 
report the effects of Depakote treatment in NH dementia residents. The drug-centered 
framework further prompts members of the psychiatric research community to produce 
relevant, unbiased information about the short- and long-term effects that psychoactive 
medications exert on cognition, behaviors, and bodily systems. 
Limitations of the Study  
One of the limitations of this study was that the sample was drawn from only two 
NHs in the United States and did not adequately represent all aspects of the NH 
population. Residents were obtained for this study through the two local NHs with 
preexisting data. Data collection served as a limitation because there were several 
selection criteria: needing to be on Depakote for the 1-year period, having a diagnosis of 
dementia, and receiving Depakote treatment for agitation/behaviors. Residents who were 





Another limitation was that I assumed that the NH MDS coordinators were 
answering the MDS questions accurately and completing the resident/staff interviews on 
time. If the resident/staff interviews were not completed each quarter, scores could be 
inaccurate. The credibility of findings depended on the honesty and diligence of the data 
providers. 
Implications for Social Change  
Implications for social change include assessing the impact and efficacy of a 
common yet largely unexamined invasive treatment on an underserved, vulnerable 
population. Much of the existing research on Depakote and STM has been solely focused 
on the adverse effects of various psychotropic medications and cognitive functioning; 
however, this study specifically employed Depakote because it tends to be the most 
widely used medication to treat agitation in NH dementia residents (Richter, Mann, 
Meyer, Haastert, & Köpke, 2011). Also, this study specifically looked at how Depakote 
effected STM in NH dementia residents. There has been noted research on Depakote and 
its impact on cognitive functioning; however, research is lacking in STM. Research on 
this subject is fairly complex because members of the target population are often unable 
to express how they feel. Therefore, cognitive testing is important in this population in 
that it allows for the determination of memory loss. The most common form of memory 
loss in dementia residents starts with STM, and this does not seem to be a focus of much 
of the existing literature. Therefore, this study focused on how Depakote impacts STM in 





This research adds to the literature of research conducted solely on the impact of 
Depakote on agitation and STM in NH dementia residents. This research can provide 
avenues for social change by providing new information to appropriate professionals, on 
the most common treatment (i.e., Depakote) for a prevalent and exigent societal problem 
(i.e., BPSD). 
Recommendations for Future Research 
The current study has increased understanding of the impact of Depakote on 
agitation and STM in NH dementia residents over a 1-year period. It is recommended that 
additional research is done on this topic. The current study used quantitative measures; 
however, conducting this study using qualitative measures would possibly produce more 
comprehensive analysis and statistical significance as it would gather specific themes that 
could be explored to address the impact of Depakote on agitation and STM. Results 
indicated there was no significant difference in agitation and STM scores among the 16 
residents in this study. Future research should also include residents chosen with specific 
demographics and characteristics to broaden the sample criteria.  
As research has previously noted, the impact or benefits of psychoactive 
medications are not exclusive to one specific medication; thus, the anticonvulsant agent 
Depakote may have some advantages when used for agitation and aggression in dementia 
residents due to its lower rates of drug interactions and adverse effects in the dementia 
population (Meinhold et al., 2005). Previous research has found the use of Depakote for 





has been found that Depakote may have multiple beneficial effects in NH dementia 
residents with a history of dementia with behavioral problems. Additional research is 
needed in the areas of (a) using Depakote treatment as a secondary agent and (b) starting 
the treatment earlier in the dementia process to explore if it may have more beneficial 
effects. 
Recommendations for Action  
This study provides an understanding of the impact of Depakote on agitation and 
STM in NH dementia residents over a 1-year period. There were no significant 
relationships or differences between Depakote and agitation scores. A total of 16 
residents scores were measured and compared to the other with random effects over a 1-
year period. Agitation scores varied but were close enough that statistical analysis 
showed no significance. With this information, avenues for additional exploration on 
Depakote and agitation in NH dementia residents can be explored by utilizing a larger 
sample and additional demographics to highlight the effects of Depakote in a larger 
population with demographics for a substance to the research.  
Although this study did not indicate any statistical significance among Depakote 
and STM scores, there is now research on STM and how it is impacted by Depakote 
treatment. Research has now highlighted that STM scores improved from Depakote start 
date, though not significantly during a 1-year period. This information can potentially 
help professionals when completing cognitive testing in NH dementia residents on 





Depakote treatment can play a role in STM; however, appropriate measures must be 
taken to maintain confidentiality and safety among members of this vulnerable 
population. 
Conclusion  
This current study focused on a sample of 16 NH residents with a diagnosis of 
dementia receiving Depakote treatment for agitation. The research was designed to utilize 
preexisting data from the consulting pharmacy and two local NHs. The results of the 
repeated measures ANOVA with within-subjects did not reveal a significant relationship 
between Depakote and levels of agitation or STM. Results of repeated measures ANOVA 
with within subjects and random effects did not reveal a significant relationship between 
Depakote and agitation scores but revealed an improvement in STM scores. Although 
this study revealed an improvement in STM scores, it did not reveal any significant 
difference in STM scores over the 1-year study period. Adding a confounding variable, 
length of time on Depakote did not show any significance in agitation or STM scores. 
The findings from this study suggest that there may be other factors moderating agitation 
and STM scores, and further exploration is warranted on the impact of Depakote on 
agitation and STM in NH dementia residents over a 1-year period.  
Results from this study also suggest that there is much more to be explored among 
the NH dementia population. Because dementia residents are unable to provide 
information themselves, the researcher must rely on the NH staff for information. It is 





data is accurate and honest. Without accuracy, results can be affected. Results of this 
study also reveal that the sample may be too small and that a larger sample would provide 
more substance to the research. 
Understanding of these results may lead to earlier administration of Depakote to 
NH dementia residents. This research can provide insight to mental health professionals, 
medical staff, NH staff, and psychologists regarding the treatment needs of NH dementia 
residents experiencing BPSD. I hope that these findings will bring much-needed 
awareness to this underserved population so that appropriate care and treatment are 
enforced, policies for treatment interventions developed and implemented, education 
made available, and future research made a priority. Research can give a voice to this 
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Appendix D: Example MDS Section C (Cognitive) and Section E (Behavioral) 
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